The Learning Portal will be under maintenance Saturday, 8 August between 6 AM and 6 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.

RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
Regulatory Focus™ > News Articles > 2019 > 12 > EMA: Signal Management Improved After Pharmacovigilance Reforms

EMA: Signal Management Improved After Pharmacovigilance Reforms

Posted 11 December 2019 | By Michael Mezher 

EMA: Signal Management Improved After Pharmacovigilance Reforms

The European Medicines Agency (EMA) on Wednesday touted the results of a six-year review that show improvements to signal management for medicines within the EU following pharmacovigilance reforms in 2012.
 
In 2010 and 2012, the EU introduced new directives and regulations amending its pharmacovigilance requirements, which came into force under the new pharmacovigilance legislation.
 
“In the first six years since the implementation of the 2012 EU pharmacovigilance legislation, the EU network has demonstrated its ability to reliably detect, assess and manage safety signals for medicines,” EMA said.
 
According to the review, more than 26,000 potential signals were reviewed by the EU network during the first six-year mandate of EMA’s Pharmacovigilance Risk Assessment Committee (PRAC), resulting in 563 validated signals, of which 465 were confirmed. During that time, the PRAC held nearly 800 initial and follow-up discussions related to 453 of the confirmed signals, with the remaining 12 held in the month after the cutoff for the review.
 
“The reduction from 26,000 to 563 validated signals is based on the well-established signal validation approaches, including whether something is already labeled in the product information,” the authors of the review wrote.
 
EMA notes that more than half of PRAC’s recommendations related to the signals it reviewed led to changes in product information for the drug the signal pertained to.
 
EMA also said that some of the risk minimization measures were “made in as few as five days of a signal being confirmed,” with a median review time of five months.
 
EMA, Review

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe